PDS Biotech receives Notice of Allowance for PDS0101 patent.

jueves, 22 de enero de 2026, 8:49 am ET1 min de lectura
PDSB--

PDS Biotechnology has received a Notice of Allowance for a patent application for its lead asset, PDS0101. The patent, titled "Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes," will grant broad composition of method of use claims and enhance the company's intellectual property estate. The Versamune platform and PDS0101 value are reinforced as the company advances through late-stage development.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios